CASI - CASI Pharmaceuticals Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

87.24M

Cash

19.66M

Avg Qtr Burn

N/A

Short % of Float

3.66%

Insider Ownership

35.77%

Institutional Own.

18.01%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EVOMELA (melphalan) Details MM (Multiple Myeloma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Inaticabtagene Autoleucel (CNCT-19) (Anti-CD19) Details Non-Hodgkin lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BI-1206 (Anti-FcyRIIB antibody) + rituximab Details Blood cancer, Non-Hodgkin lymphoma, Solid tumor/s, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-5339 Details Multiple myeloma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.